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ABSTRACT 
 
Background: A landmark study suggested that wide excision of intermediate-thickness 
melanoma with sentinel lymph node biopsy (SLNB) and subsequent completion lymph 
node dissection (CLND) for regional disease may improve prognostication and disease-
free survival (DFS) compared with those undergoing wide excision alone.  However, 
these benefits were relatively small and not associated with an improvement in disease-
specific survival (DSS).  It remains unknown if SLNB and subsequent treatments are 
beneficial in elderly patients who have a decreased overall (OS) due to other causes. 
 
Methods: Adults ≥ 70 years of age, who underwent surgical intervention for 
intermediate-thickness cutaneous melanoma from 2000-2013 were identified from a 
prospectively-maintained database.  Clinicopathologic variables measured included age, 
gender, anatomic site, histologic type, tumor thickness, ulceration, receipt and result of 
SLNB, completion of CLND, OS, and DFS. 
 
Results: Ninety-one patients underwent excision of an intermediate-thickness melanoma.  
Forty-nine patients (54%) received a SLNB.  Seven of these biopsies (14%) were 
positive, and five patients went on to receive CLND.  Five-year OS was 41% in patients 
who did not receive SLNB and 52% in patients who did receive SLNB (p=0.11).  DFS 
was similar between groups independent of receipt of SLNB. 
v 
Conclusion: Among elderly patients with intermediate-thickness melanoma, patients who 
received SLNB had similar 5-year OS and DFS compared with those who did not receive 
SLNB.  Routine SLNB for intermediate-thickness melanoma patients may not 
significantly change outcomes for this age group, and clinical decision-making should 
consider individual patient comorbidities and goals of care. 
 
vi 
TABLE OF CONTENTS 
 
Front Matter 
Title Page………………………………………………………….……………………….i 
Signature Page……………………………………………………………...……………..ii 
Acknowledgements…………………………………………………………….………...iii 
Abstract…………………………………………………………………………………...iv 
Table of Contents…………………………………………………………………………vi 
List of Tables…………………………………………………………………………….vii 
List of Figures…………………………………………………………………………...viii 
List of Abbreviations and Acronyms……………..………………………………………ix 
 
Body Matter 
Chapter I: Introduction………………………………………………………………….…1 
Chapter II: Methods……………………………………………………………………….3 
Chapter III: Results………………………………………………………………………..6 
Chapter IV: Discussion…………………………………………………………………..14 
 
Back Matter 
References………………………………………………………………………………..17 
vii 
LIST OF TABLES 
 
Table 3.1: Patient characteristics 
Table 3.2: Reasons patients did not undergo sentinel lymph node biopsy 
 
viii 
LIST OF FIGURES 
 
Figure 3.1: Lymph node evaluation in elderly patients with intermediate-thickness 
cutaneous melanoma 
Figure 3.2: Overall survival for elderly patients with intermediate-thickness cutaneous 
melanoma 
Figure 3.3: Disease-free survival for elderly patients with intermediate-thickness 
cutaneous melanoma 
Figure 3.4: Causes of death in elderly patients with intermediate-thickness cutaneous 
melanoma 
 
ix 
LIST OF ABBREVIATIONS AND ACRONYMS 
 
CLND – completion lymph node dissection 
DFS – disease-free survival 
MSLT – Multicenter Selective Lymphadenectomy Trial 
OS – overall survival 
SLNB – sentinel lymph node biopsy 
DSS – disease-specific survival 
NED – no evidence of disease 
AWD – alive with disease 
DOD – died of disease 
DOC – died of other causes 
DUC  - died of unknown causes 
 
1 
CHAPTER I: INTRODUCTION 
 
 Melanoma is the fourth most common malignancy in American men and the 
seventh most common malignancy in women, with 76,000 cases diagnosed in 2014. The 
incidence rate of this malignancy appears to be increasing.1  While disease-specific 
mortality has decreased among patients younger than 65 years, these rates have increased 
among those 65 years and older.2  
The clinical practice guidelines from the National Comprehensive Cancer 
Network (NCCN), the American Society of Clinical Oncology (ASCO), and the Society 
of Surgical Oncology (SSO) recommend that patients with intermediate-thickness 
melanoma undergo sentinel lymph node biopsy (SLNB), with subsequent completion 
lymph node dissection (CLND), if the SLNB is found to have metastatic disease.3–5  
These recommendations are based on the results of the landmark Multicenter Selective 
Lymphadenectomy Trial-I (MSLT-I).  This trial randomized a total of 1269 patients with 
intermediate-thickness primary melanoma to wide excision with observation of lymph 
nodes or to wide excision with SLNB.  The study reported a greater DFS in those 
undergoing SLNB, and subgroup analysis further demonstrated a benefit to CLND in the 
setting of a positive sentinel lymph node.6 
 However, it remains unclear if the results of the MSLT-I can be generalized to 
elderly individuals for a variety of reasons. First, the median age of the subjects in this 
trial was 53 years.  Furthermore, despite the NCCN, ASCO, and SSO recommendations,  
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observational studies have shown that adherence to these guidelines is poor, particularly 
among elderly patients.  In a study of patients with positive sentinel lymph nodes, the 
presence of non-adherence to guideline-recommended CLND was not associated with a 
reduction in survival.7  Finally, it is well known that patients >70 years have an increased 
likelihood of dying from other causes. While it has yet to be proven that SLNB and its 
subsequent CLND improve survival in the elderly with intermediate-thickness 
melanomas, national recommendations currently do not provide age-specific 
recommendations that take into account both mortality from disease and mortality due to 
other causes, the latter of which is a more dominant issue in the elderly population. 
 The aims of this study are to examine current practices in regional management of 
intermediate-thickness cutaneous melanoma in the elderly, and to determine if SLNB is 
associated with improved overall and disease-free survival. 
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CHAPTER II: METHODS 
 
This retrospective review of our institution’s prospectively-maintained melanoma 
tumor registry was performed after approval from our institutional review board.  Our 
institution is a tertiary-care referral center for cancer, treating patients primarily from 
central Massachusetts and nearby regions of Connecticut and New Hampshire.  Patients 
were included if they were ≥70 years and underwent surgical treatment for intermediate-
thickness cutaneous melanoma between 2000-2013.  The age cut-point of 70 years was 
chosen because of prior studies that showed differences in the natural history of disease 
in this age group, compared with patients younger than 70.8–10  Intermediate-thickness 
disease was defined as pathologically confirmed melanoma with a Breslow depth of 1-4 
mm on biopsy or wide excision specimen.  Biopsies that were performed at referring 
institutions were re-reviewed by pathologists at our institution.  Patients were excluded if 
they were preoperatively diagnosed with regional or distant metastases. 
 Demographic data (age, gender), comorbidity information, and tumor 
characteristics (anatomic site, Breslow thickness, histologic subtype, presence of adverse 
features [ulceration or mitoses]) were collected.  Comorbidity information from the 
medical record was used to calculate the Charlson comorbidity index.11  The independent 
variable in our study was the receipt of SLNB.  Data were collected on receipt of SLNB, 
positivity of SLNB, and receipt of CLND.  
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 The primary study outcome was overall survival (OS), which was calculated from 
date of definitive primary melanoma surgery to date of death.  Date of death and cause of 
death (when available) were confirmed with social security death records and the tumor 
registry.  DFS was calculated from the date of definitive primary melanoma surgery to 
the date of recurrence detection. 
 Vital status was classified as: no evidence of disease (NED), alive with disease 
(AWD), died of disease (DOD), died of other causes (DOC), and died of unknown causes 
(DUC).  NED was defined as patients without detected recurrent disease during follow-
up examinations.  AWD was defined as living patients with detected recurrent disease.  
DOD was defined as either (1) patients who had a cause of death that was directly 
disease-related, or (2) patients with advanced metastatic or locally aggressive disease, 
who had made decisions regarding goals of care related to their disease burden.  DOC 
was defined as either (1) patients who had a cause of death obviously unrelated to 
disease, such as a trauma, or (2) patients who may have had an unclear cause of death, 
but they had recent follow-up prior to death with documented lack of melanoma 
recurrence.  DUC was defined as either (1) patients without recent follow-up prior to 
death, or (2) patients with a melanoma disease burden but with a competing cause of 
death, such as those with two or more known primary malignancies. 
 Demographic and clinical characteristics were compared between the respective 
treatment groups in a univariate fashion, using t-tests and chi-squared tests for continuous 
and categorical variables, respectively.  Kaplan-Meier curves, the log-rank test, and the  
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Cox proportional hazard model were used for survival analysis, both for OS and DFS.  
Multivariate analysis using the Cox proportional hazard model was done by adjusting for 
gender, age, primary site, and tumor thickness.  The alpha level was set to 0.05 for all 
measures of statistical significance.  Stata version 13 (StataCorp, College Station, TX) 
was used for all statistical analyses. 
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CHAPTER III: RESULTS 
 
 A total of 91 elderly patients with intermediate-thickness melanoma were 
identified out of 228 total elderly patients in the melanoma tumor registry.  The patients 
were 55% male, and the mean age was 80.1 years (SD 6.7 years).  Forty-nine patients 
(53.8%) underwent SLNB, while 42 (46.2%) underwent clinical observation of the nodal 
basin.  Patients who received SLNB were significantly more likely to be male and 
younger than those who did not receive SLNB (p<0.05).  Patients who did not receive 
SLNB were more likely to have primary tumors of the head or neck (p<0.01).  There was 
no statistically significant difference between the two groups, with regard to Charlson 
Comorbidity Index, histologic type, or Breslow depth (Table 3.1). The reasons to forgo 
SLNB, when available, include patient preference and co-morbidities that would preclude 
further management (Table 3.2). 
 Of the 49 patients who received SLNB, seven (14.3%) were found to have 
metastatic disease.  Of these seven patients, five went on to receive CLND.  The 
remaining two patients demonstrated progression of disease before CLND could be 
performed (Figure 3.1). 
 The 5-year OS in patients who did and did not receive SLNB was similar: 52% 
and 41%, respectively (p=0.11; Figure 3.2).  OS was also not statistically different on 
multivariate analysis (hazard ratio (HR): 1.44, 95% confidence interval (CI): 0.62-3.34, 
p=0.39). 
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 Patients who did and did not receive SLNB had similar 5-year DFS: 77% and 
79%, respectively (p=0.87; Figure 3.3).  DFS remained not significantly different on 
multivariate analysis (HR: 1.65, 95% CI: 0.39-7.06; p=0.50). 
 Of the 91 study patients, 47 (51.7%) had died at the time of this study.  Of the 
remaining 44, 1 was AWD, and 43 were NED.  The causes of death could be determined 
in 30 cases.  Of these, 9 died of disease and 21 died of other causes. In 17 cases, the cause 
of death could not be determined if the patients had been lost to follow-up prior to death 
or if their causes of death were ambiguous.  In comparing the patients in whom the cause 
of death could be confirmed, patients who received SLNB were more likely to die from 
melanoma, while those who did not receive SLNB were more likely to die from other 
causes (p=0.02; Figure 3.4). 
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Table 3.1: Patient characteristics 
Variable Received SLNB 
(N=49) 
No SLNB 
(N=42) 
p-
value 
Male gender, N (%) 32 (65%) 18 (43%) 0.03 
Age at diagnosis (years), mean (SD) 75.9 (4.2) 85.1 (5.6) < 0.01 
Charlson Comorbidity Index 
(unadjusted), mean (SD) 
1.41 (1.32) 1.79 (1.60) 0.22 
Site of primary tumor, N (%) 
Head/neck 
Torso 
Upper extremity 
Lower extremity 
Other 
 
11 (22%) 
16 (33%) 
12 (24%) 
9 (18%) 
1 (2%) 
 
27 (64%) 
3 (7%) 
7 (17%) 
5 (11%) 
0 (0%) 
< 0.01 
Histologic type, N (%) 
Superficial spreading 
Nodular 
Lentigo maligna 
Acral lentiginous 
Nevoid 
Desmoplastic 
Unclassified 
 
19 (39%) 
11 (22%) 
2 (4%) 
3 (6%) 
1 (2%) 
3 (6%) 
10 (20%) 
 
23 (55%) 
8 (19%) 
5 (12%) 
1 (2%) 
0 (0%) 
2 (5%) 
3 (7%) 
0.27 
Breslow depth (mm), mean (SD) 2.15 (0.91) 2.10 (0.81) 0.80 
SLNB – sentinel lymph node biopsy; SD – standard deviation 
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Table 3.2: Reasons patients did not undergo sentinel lymph node biopsy (n=42) 
 
Reason Number of cases*  
Patient would not be a candidate for CLND 
and/or adjuvant therapy 
11 
Patient did not want more aggressive 
treatment beyond excision 
11 
Physician recommended against SLNB 
because of patient age and/or comorbidities 
10 
Tumor board consensus decision 3 
SLNB attempted, but no sentinel nodes 
found intra-operatively 
2 
Not documented 16 
*The cases sum up to greater than the total number of cases because some patients had 
multiple reasons cited. 
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Figure 3.1: Lymph node evaluation in elderly patients with intermediate-thickness 
cutaneous melanoma 
 
 
SLNB – sentinel lymph node biopsy; CLND – completion lymph node dissection 
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Figure 3.2: Overall survival for elderly patients with intermediate-thickness cutaneous 
melanoma 
 
p=0.11 
SLNB – sentinel lymph node biopsy 
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Figure 3.3: Disease-free survival for elderly patients with intermediate thickness 
cutaneous melanoma 
 
p=0.87 
SLNB – sentinel lymph node biopsy 
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Figure 3.4: Causes of death in elderly patients with intermediate-thickness cutaneous 
melanoma 
 
 
p=0.02 
SLNB – sentinel lymph node biopsy 
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CHAPTER IV: DISCUSSION 
 
 In this retrospective study, about half of the elderly patients with intermediate-
thickness melanoma underwent SLNB.  The patients for whom SLNB was deferred were 
more likely to be female, older, and have head/neck primary tumors.  The most common 
reasons for deferral were generally related to the patients’ age and comorbidities, a lack 
of candidacy for CLND and/or adjuvant therapy if the SLNB were positive, and patient 
desire to not to pursue aggressive treatment. 
 This compliance pattern is consistent with trends seen in the National Cancer 
Database (NCDB).  Bilimoria et al. showed that only 50% of patients of all ages with a 
metastatic sentinel lymph node went on to receive CLND.  Patients aged >75 years were 
even less likely to undergo a CLND after a positive sentinel lymph node (42.7%).12  The 
NCDB data does not contain information as to the reasons why patients defer CLND 
despite clinical guidelines.  However, a retrospective patient series at Memorial Sloan-
Kettering Cancer Center showed similar rates of CLND.  Chart reviews from that study 
demonstrated that the most common reason for forgoing CLND was patient refusal 
(45%), although the study could not ascertain the exact reason for this decision.7  While 
these studies examined CLND rather than SLNB, the patients and clinicians in our 
retrospective study believed that there would not be much utility in doing a SLNB if it 
was already known that a subsequent CLND or additional treatment would be deferred.   
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In these cases, a SLNB would only provide prognostic information while subjecting 
patients to potential complications. 
 Our study demonstrates that elderly patients have similar OS and DFS, 
independent of receipt of a SLNB.  Several other retrospective studies have compared the 
oncologic outcomes of patients of all ages who undergo SLNB with those who undergo 
observation.13–19  The trend in these studies shows that SLNB is associated with improved 
DFS but, similar to our study, not with DSS or OS. 
 A randomized trial that compares elderly patients who undergo CLND with those 
who undergo observation for positive SLNB could elucidate the relationship between 
subclinical lymph nodes and survival.  This is one of the aims of MSLT-II, which is still 
ongoing with a 10-year follow-up period.  The trial includes adult patients ≥ 18 years, but 
subgroup analysis may provide some information about the role of SLNB and CLND in 
the elderly.20 
 Our study has several important limitations.  It is a retrospective study of patients 
treated at a single institution.  The patients were not randomized to SLNB.  Furthermore, 
because our institution is a tertiary-care referral center for cancer, the patient follow-up 
for medical issues unrelated to melanoma is variable.  However, follow-up for melanoma 
is consistently performed at our institution, which allows for more reliable recurrence 
documentations.  Therefore, patients with DUC were more likely to be DOC rather than 
DOD, although we did not incorporate this assumption in our calculations. 
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 The decision to undergo a surgical procedure for any patient, and especially the 
elderly, is a complex process that involves discussion between the physician, patient, and 
patient caretakers.  This study shows that elderly patients who received SLNB had similar 
OS and DFS independent of receipt of SLNB.  Routine SLNB for intermediate-thickness 
cutaneous melanoma may not significantly change outcomes for this age group and may 
not be necessary in this patient subpopulation.  Therefore, clinical decision-making 
should continue to take into account both tumor- and patient-specific factors. 
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